Related Experiment Video
Updated: Aug 25, 2026

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt
Published on: May 7, 2015
Management of Hepatotoxicity Induced by the Use of Olanzapine
Yunus Emre Dönmez1, Özlem Özcan1, Nusret Soylu1
11 Department of Child and Adolescent Psychiatry, Inonu University , Malatya, Turkey .
Abstract:
Numerous drugs cause hepatotoxicity clinically or biologically. Neuropsychiatric drugs constitute 16% of these drugs. The occurrence of hepatotoxicity induced by the use of olanzapine is expressed by the researchers. In such cases, generally the dose of olanzapine is reduced or the drug is completely discontinued and the treatment of the patient fails. The aim of this study is to report the case for whom elevated liver enzymes were observed but the process was managed without changing treatment dose and drug and to discuss this case with literature information. The present study has characteristics of being the first in the literature concerning management of the process.
Insights
This study presents a case of managing elevated liver enzymes caused by olanzapine without altering the dosage. This approach offers a novel strategy for patients experiencing drug-induced liver injury during neuropsychiatric treatment.
Area of Science:
- Hepatology
- Clinical Pharmacology
- Neuropsychiatry
Background:
- Drug-induced liver injury (DILI) is a significant clinical concern, with neuropsychiatric medications accounting for a notable percentage of cases.
- Olanzapine, a commonly used antipsychotic, has been associated with hepatotoxicity, often necessitating dose reduction or discontinuation.
- Current management strategies for olanzapine-induced hepatotoxicity typically involve altering the treatment regimen, potentially leading to therapeutic failure.
Purpose of the Study:
- To report a unique case of olanzapine-induced elevated liver enzymes managed successfully without changing the drug dose or formulation.
- To discuss the clinical implications and literature context of this alternative management approach for DILI.
- To highlight a potentially novel strategy for managing olanzapine-associated hepatotoxicity.
Main Methods:
- Case report detailing a patient who developed elevated liver enzymes during olanzapine treatment.
- Clinical monitoring of liver function tests and patient's response to continued olanzapine therapy at the established dose.
- Comprehensive literature review on olanzapine-induced hepatotoxicity and its management.
Main Results:
- The patient exhibited elevated liver enzymes, indicative of hepatotoxicity, while on olanzapine therapy.
- The elevated liver enzymes were successfully managed and normalized without any modification to the olanzapine dose or discontinuation of the drug.
- This case demonstrates the feasibility of continuing olanzapine treatment in specific instances of drug-induced liver injury.
Conclusions:
- Management of olanzapine-induced hepatotoxicity may not always require dose adjustment or drug cessation.
- This case provides evidence for a novel, conservative management approach that preserves therapeutic continuity.
- Further research is warranted to elucidate the mechanisms and patient selection criteria for this management strategy.
Related Concept Videos
Psychosis and Antipsychotic Drugs: Overview
Psychosis: Goals of Pharmacotherapy
Mania and Antimanic Drugs: Overview
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Pharmaceutical Poisoning: Treatment Strategies

